TAIKO PHARMACEUTICAL CO., LTD. Logo

TAIKO PHARMACEUTICAL CO., LTD.

Manufactures OTC gastrointestinal medicine and leading infection control products.

4574 | T

Overview

Corporate Details

ISIN(s):
JP3442200006
LEI:
Country:
Japan
Address:
吹田市内本町三丁目34番14号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Taiko Pharmaceutical Co., Ltd. is a manufacturer and distributor specializing in pharmaceuticals and infection control products. The company operates through three primary business segments: Pharmaceutical, Infection Control, and Others. Its Pharmaceutical division is centered on its flagship product, Seirogan, an over-the-counter gastrointestinal medication with a history of over 100 years, used for treating symptoms like diarrhea and loose stools. The Infection Control division, a significant contributor to company revenue, develops and markets products including a leading brand of airborne disinfectants. The company is engaged in ongoing research and development to support its product lines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 08:35
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-08-08 08:34
Interim Report
半期報告書-第80期(2025/01/01-2025/12/31)
Japanese 197.8 KB
2025-04-01 08:45
Post-Annual General Meeting Information
臨時報告書
Japanese 22.1 KB
2025-03-28 07:36
Regulatory News Service
臨時報告書
Japanese 19.1 KB
2025-03-28 07:35
Governance Information
内部統制報告書-第79期(2024/01/01-2024/12/31)
Japanese 22.1 KB
2025-03-28 07:33
Registration Form
確認書
Japanese 8.1 KB
2025-03-28 07:32
Annual Report
有価証券報告書-第79期(2024/01/01-2024/12/31)
Japanese 1011.8 KB
2024-08-09 08:34
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-08-09 08:33
Interim Report
半期報告書-第79期(2024/01/01-2024/12/31)
Japanese 210.9 KB
2024-05-10 08:37
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-05-10 08:35
Quarterly Report
四半期報告書-第79期第1四半期(2024/01/01-2024/03/31)
Japanese 164.9 KB
2024-04-01 08:14
Post-Annual General Meeting Information
臨時報告書
Japanese 23.7 KB
2024-03-28 07:30
Governance Information
内部統制報告書-第78期(2023/01/01-2023/12/31)
Japanese 22.1 KB
2024-03-28 07:28
Registration Form
確認書
Japanese 8.1 KB
2024-03-28 07:26
Annual Report
有価証券報告書-第78期(2023/01/01-2023/12/31)
Japanese 1.1 MB

Automate Your Workflow. Get a real-time feed of all TAIKO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TAIKO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TAIKO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.